THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Michael O'Dwyer to Protein Kinase Inhibitors

Back to Details
This is a "connection" page, showing publications Michael O'Dwyer has written about Protein Kinase Inhibitors.
Michael O'Dwyer
Connection Strength
0.280
Protein Kinase Inhibitors
  1. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019 06 25; 3(12):1799-1807.
    View in: PubMed
    Score: 0.145
  2. The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment. Br J Haematol. 2018 09; 182(5):654-669.
    View in: PubMed
    Score: 0.135
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES